Phase 2/3 Izalontamab Brengitecan vs Platinum-based Chemotherapy for Mets Urothelial Cancer
Phase II/III Clinical Trial
CA244-0012 IZABRIGHT-BLADDER01: A RANDOMIZED OPEN-LABEL PHASE 2/3 TRIAL OF IZALONTAMAB BRENGITECAN VERSUS PLATINUM-BASED CHEMOTHERAPY FOR METASTATIC UROTHELIAL CANCER IN PARTICIPANTS WITH DISEASE PROGRESSSION ON OR AFTER AN IMMUNOTHERAPY-BASED TREATMENT